2011
Should a Sentinel Node Biopsy Be Performed in Patients with High‐Risk Breast Cancer?
Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS. Should a Sentinel Node Biopsy Be Performed in Patients with High‐Risk Breast Cancer? International Journal Of Breast Cancer 2011, 2011: 973245. PMID: 22295240, PMCID: PMC3262582, DOI: 10.4061/2011/973245.Peer-Reviewed Original ResearchAxillary diseaseSLN biopsyHigh riskNegative SLN biopsy resultsHigh-risk breast cancerNegative SLN biopsySLN biopsy resultsLymph node irradiationSentinel node biopsyBreast cancer patientsAxillary irradiationNode irradiationClinical characteristicsNodal biopsyNodal involvementNode biopsyAdditional surgeryBiopsy resultsCancer patientsBreast cancerBiopsyPatientsBayesian nomogramTest characteristicsDisease
2004
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis. Journal Of Clinical Oncology 2004, 22: 854-863. PMID: 14990641, DOI: 10.1200/jco.2004.04.158.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBreast NeoplasmsCohort StudiesCost SavingsCost-Benefit AnalysisDecision Support TechniquesDose-Response Relationship, DrugDrug Administration ScheduleDrug CostsFemaleGenes, erbB-2Genetic TestingHealth Care CostsHumansMarkov ChainsNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingQuality of LifeSurvival RateTrastuzumabTreatment OutcomeConceptsIncremental cost-effectiveness ratioMetastatic breast cancer patientsBreast cancer patientsTrastuzumab therapyCancer patientsFavourable incremental cost-effectiveness ratioTest characteristicsMetastatic breast cancerCost-effectiveness ratioEffectiveness of treatmentPositive test resultsNegative test resultsPositive resultsCost-effectiveness analysisTreatment strategiesBreast cancerHypothetical cohortTreatment candidatesHercepTest resultsPatientsClinical practiceFISH confirmationProtein overexpressionLifetime costsHercepTest